Literature DB >> 22853846

Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squamous cell carcinoma cells.

Ruan Min1, Li Siyi, Yang Wenjun, Liu Shengwen, Andrew Ow, Wang Lizheng, Zhang Chenping.   

Abstract

Increasing evidence suggests that malignant transformation can result from chronic infection, and Toll-like receptors (TLRs) may play an important role in this process. We have previously reported that the increased expression of TLR-9 is associated with tumor cell proliferation in oral cancer. However, the mechanisms involved have not been elucidated. The aim of this study was to investigate whether CpG-oligodeoxynucleotides (CpG-ODN), a special TLR-9 agonist, is able to exert the proliferation-promoting effect in human oral squamous cell carcinoma (OSCC), and to explore the possible underlying molecular mechanism. Flow cytometry, MTT, and colony formation assay were used to evaluate cell proliferation and cell cycle distribution. The mRNA and protein levels were analyzed by quantitative RT-PCR and Western blot assay. Luciferase reporter gene, EMSA, and ChIP assays were used to detect the activity of activator protein-1 (AP-1) and nuclear factor-κB (NF-κB) in HB cells. Results showed that CpG-ODN could stimulate proliferation of HB cells in a dose- and time-dependent manner with a promoted G(1) /S cell cycle progression. Increased cyclin D1 expression was detected in the nuclear region after CpG-ODN treatment. Moreover, CpG-ODN promoted nuclear translocation and activation of AP-1, which appeared to be required for TLR-9-mediated cyclin D1 expression and subsequently cell proliferation, but seemed to have little impact on NF-κB activity. Our results indicate that CpG-ODN stimulates tumor cell proliferation through TLR-9-mediated AP-1-activated cyclin D1 expression in OSCC HB cells. Pharmacologic inhibition of the TLR-9/AP-1/cyclin D1 pathway may be a new therapeutic approach for prevention as well as treatment of OSCC.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22853846     DOI: 10.1111/j.1349-7006.2012.02394.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.

Authors:  Fumi Sato-Kaneko; Shiyin Yao; Alast Ahmadi; Shannon S Zhang; Tadashi Hosoya; Megan M Kaneda; Judith A Varner; Minya Pu; Karen S Messer; Cristiana Guiducci; Robert L Coffman; Kazutaka Kitaura; Takaji Matsutani; Ryuji Suzuki; Dennis A Carson; Tomoko Hayashi; Ezra Ew Cohen
Journal:  JCI Insight       Date:  2017-09-21

Review 2.  Update of molecular pathobiology in oral cancer: a review.

Authors:  Tomonori Sasahira; Tadaaki Kirita; Hiroki Kuniyasu
Journal:  Int J Clin Oncol       Date:  2014-03-25       Impact factor: 3.402

3.  Activation of Toll-like receptor-9 promotes cellular migration via up-regulating MMP-2 expression in oral squamous cell carcinoma.

Authors:  Min Ruan; Zun Zhang; Siyi Li; Min Yan; Shengwen Liu; Wenjun Yang; Lizheng Wang; Chenping Zhang
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

4.  Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma.

Authors:  Yash Sharma; Kumud Bala
Journal:  Oncol Rev       Date:  2020-05-19

5.  Expression of p16, p53, and TLR9 in HPV-Associated Head and Neck Squamous Cell Carcinoma: Clinicopathological Correlations and Potential Prognostic Significance.

Authors:  Shu Wang; Xibing Zhuang; Caixia Gao; Tiankui Qiao
Journal:  Onco Targets Ther       Date:  2021-02-05       Impact factor: 4.147

6.  Oral squamous cell carcinoma (OSCC) tumors from heavy alcohol consumers are associated with higher levels of TLR9 and a particular immunophenotype: Impact on patient survival.

Authors:  Nicolás Bolesina; Gerardo Gatti; Silvia López de Blanc; Sabrina Dhooge; Darío Rocha; Elmer Fernandez; Ruth Ferreyra; Vanesa Palla; Verónica Grupe; Rosana Morelatto; Mariana Maccioni
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

Review 7.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

Review 8.  Toll-like receptors and cancer, particularly oral squamous cell carcinoma.

Authors:  Alison Mary Rich; Haizal Mohd Hussaini; Venkata P B Parachuru; Gregory J Seymour
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.